Pharming Group N.V.

Capital/Financing Update • Jan 5, 2010

PHARMING OBTAINS EURO 7.5 MILLION FINANCING

Leiden, The Netherlands, January 05, 2010. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it has secured a convertible debt financing of €7.5 million.

The financing has been structured in the form of a one year (non-listed) convertible debt instrument that is convertible into Pharming shares at €0.50. The debt has a coupon of 9 per cent per annum and is subordinated to the existing €10.9 million convertible bond. In addition, 15 million warrants are being issued to investors with an exercise price of €0.50 and an expiration date of December 31, 2012. Pharming has access to an additional €2.5 million under this convertible debt agreement on mutually acceptable terms to investors and the Company.

The convertible debt can be repaid in cash in whole or in part at the option of the investor if a commercialisation deal for Rhucin materialises with an upfront payment in excess of an undisclosed amount. Under specific future conditions, the conversion price and exercise price of the warrants could be reduced according to the lowest five day volume weighted average share price along with a 5% discount following a notice of conversion.

Dr. Sijmen de Vries, Chief Executive Officer of Pharming, said: "This financing provides a good basis for Pharming to work with the EMEA and FDA to bring Rhucin forward through the regulatory review process and also allows the Company to complete commercialisation partnerships for Rhucin."

Roth Capital Partners, LLC acted as financial advisor to Pharming in this transaction.

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, and nutritional products. Pharming's lead product Rhucin® for acute attacks of Hereditary Angioedema has passed clinical development stage and the Market Authorization Application is under review with EMEA. Prodarsan® is in early stage clinical development for Cockayne Syndrome and lactoferrin for use in food products The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Additional information is available on the Pharming website, http://www.pharming.com.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.

Contact:

Ms. Marjolein van Helmond, Pharming Group NV, T: +31 (0)71 52 47 431 or +31 (0)6 109 299 54